Evidence map›Paper›PMID 30421447›Full record

Trial reportBritish journal of clinical pharmacology2019

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Minh P Lê, Marie-Laure Chaix, François Raffi, Sylvie Chevret, Sébastien Gallien, Christine Katlama, Pierre Delobel, Yazdan Yazdanpanah, Juliette Saillard, Jean-Michel Molina and 2 more

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Minh P LêIAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and INSERM, Paris, France.ORCID 0000-0002-4670-8288
Marie-Laure ChaixAP-HP, Hôpital Saint Louis, Laboratoire de Virologie, INSERM U941, Université Denis Diderot Paris VII, F-75010, Paris, France.
François RaffiDepartment of Infectious Diseases, Hotel-Dieu Hospital, INSERM CIC 1413, Nantes University Hospital, Nantes, France.
Sylvie ChevretAP-HP, Hôpital Saint Louis, SBIM-URC, Paris, France.
Sébastien GallienAP-HP, CHU Henri Mondor, Service d'Immunologie Clinique et Maladies Infectieuses, Créteil, France.
Christine KatlamaAP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France.
Pierre DelobelCHU de Toulouse, Service de Maladies Infectieuses et Tropicales, Toulouse, France.
Yazdan YazdanpanahIAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and INSERM, Paris, France.
Juliette SaillardFrance Recherche Nord & Sud SIDA-HIV Hépatites (ANRS), Paris, France.
Jean-Michel MolinaAP-HP, Hôpital Saint Louis, Service de Maladies Infectieuses et Tropicales, INSERM U941, Université Denis Diderot Paris VII, F-75010, Paris, France.
Gilles PeytavinIAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and INSERM, Paris, France.
ANRS-165 DARULIGHT study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultDarunavirDose-Response Relationship, DrugDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationHIV-1HIV InfectionsHIV Protease InhibitorsHumansMaleMiddle AgedProspective StudiesReverse Transcriptase InhibitorsRitonavirRNA, ViralDarunavirDrug CombinationsHIV Protease InhibitorsReverse Transcriptase InhibitorsRitonavirRNA, Viraldarunavirdose reductionseminal and blood plasmaunbound total

Identifiers

PMID30421447
PMCPMC6303241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.